[go: up one dir, main page]

CL2012001293A1 - Uso del compuesto 2-(4-metilfenil)-6-(metil)quinolina para inhibor la agragacion de la proteina tau en una persona dque sufre alzheimer - Google Patents

Uso del compuesto 2-(4-metilfenil)-6-(metil)quinolina para inhibor la agragacion de la proteina tau en una persona dque sufre alzheimer

Info

Publication number
CL2012001293A1
CL2012001293A1 CL2012001293A CL2012001293A CL2012001293A1 CL 2012001293 A1 CL2012001293 A1 CL 2012001293A1 CL 2012001293 A CL2012001293 A CL 2012001293A CL 2012001293 A CL2012001293 A CL 2012001293A CL 2012001293 A1 CL2012001293 A1 CL 2012001293A1
Authority
CL
Chile
Prior art keywords
inhibit
compound
alzheimer
tau protein
quinoline
Prior art date
Application number
CL2012001293A
Other languages
English (en)
Inventor
Ricardo Maccioni
Leonardo Navarrete
Martin Aurelio San
Original Assignee
Univ Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Chile filed Critical Univ Chile
Publication of CL2012001293A1 publication Critical patent/CL2012001293A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuesto derivado de quinolina; uso de dicho compuesto para inhibir la agregación de la proteína TAU, útil en la enfermedad de Alzheimer; método para inhibir la agregación de la proteína TAU.
CL2012001293A 2010-04-29 2012-05-18 Uso del compuesto 2-(4-metilfenil)-6-(metil)quinolina para inhibor la agragacion de la proteina tau en una persona dque sufre alzheimer CL2012001293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/770,284 US8198300B2 (en) 2010-04-29 2010-04-29 Method for preventing tau protein aggregation and treating Alzheimer's disease with a quinoline derivative compound

Publications (1)

Publication Number Publication Date
CL2012001293A1 true CL2012001293A1 (es) 2013-02-22

Family

ID=44858713

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001293A CL2012001293A1 (es) 2010-04-29 2012-05-18 Uso del compuesto 2-(4-metilfenil)-6-(metil)quinolina para inhibor la agragacion de la proteina tau en una persona dque sufre alzheimer

Country Status (5)

Country Link
US (1) US8198300B2 (es)
EP (1) EP2567954B1 (es)
JP (1) JP5283802B2 (es)
CL (1) CL2012001293A1 (es)
WO (1) WO2011134098A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20180141911A1 (en) * 2015-05-14 2018-05-24 Northeastern University Quinoline Derivatives for Diagnosis and Treatment of Alzheimer's Disease
TWI587860B (zh) 2016-05-06 2017-06-21 國立臺灣師範大學 喹啉衍生化合物用於製備Ｔａｕ蛋白病變類疾病之醫藥組成物上之用途
KR20230127371A (ko) * 2016-11-01 2023-08-31 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
EP3577109A4 (en) 2017-01-31 2020-11-18 Arvinas Operations, Inc. CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
CN107488144B (zh) * 2017-08-09 2021-06-04 复旦大学 一种可以特异性结合并能抑制Tau蛋白聚集的分子及其制备方法和应用
EP3743066A4 (en) 2018-01-26 2021-09-08 Yale University IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2022178283A1 (en) * 2021-02-19 2022-08-25 The Regents On The University Of California Compositions and methods for treating tauopathies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1088818B1 (en) * 1999-10-01 2004-11-03 F. Hoffmann-La Roche Ag Quinolin-4-yl derivatives
EP1574500A1 (en) 2002-12-16 2005-09-14 BF Research Institute, Inc. Quinoline derivative as diagnostic probe for disease with tau protein accumulation
US7117830B1 (en) 2005-11-23 2006-10-10 Ford Global Technologies, Llc System and method for direct injection of gaseous fuel into internal combustion engine
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
CA2713998A1 (en) 2008-01-28 2009-08-06 Janssen Pharmaceutica N.V. 6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of.beta.-secretase (bace)
JP2011510993A (ja) 2008-01-29 2011-04-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ β−セクレターゼ（ＢＡＣＥ）阻害剤として有用な２−アミノ−キノリン誘導体
WO2009133692A1 (ja) 2008-04-30 2009-11-05 興和株式会社 キノリン化合物

Also Published As

Publication number Publication date
WO2011134098A1 (es) 2011-11-03
EP2567954B1 (en) 2014-06-18
JP5283802B2 (ja) 2013-09-04
EP2567954A4 (en) 2013-05-01
US20110269793A1 (en) 2011-11-03
JP2013523785A (ja) 2013-06-17
US8198300B2 (en) 2012-06-12
EP2567954A1 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
CL2012001293A1 (es) Uso del compuesto 2-(4-metilfenil)-6-(metil)quinolina para inhibor la agragacion de la proteina tau en una persona dque sufre alzheimer
EP2902839A4 (en) CONTACT LENS WITH SHORT-SIZE PROGRESSION SUPPRESSION AND CONTACT LENS SET WITH SHORT-SIZE PROGRESSION SUPPRESSION
AR109356A2 (es) Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona
EA201391392A1 (ru) Синтетические наноносители с осмотически опосредованным высвобождением
EA201400838A1 (ru) ЗАМЕЩЕННЫЕ АМИДИНОМ β-ЛАКТАМЫ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ СРЕДСТВ
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201201357A1 (ru) Антитела к cd40
MX388893B (es) Formulaciones de anticuerpos estables acuosas.
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201501142A1 (ru) Гетероциклические соединения в качестве средств для борьбы с вредителями
EP2968973A4 (en) FOR THE EYE IMPROPER LASER RADIATION IN EYE SURGERY
JP2012204203A5 (es)
EP2843050A4 (en) AFFECTED ON FRUCTOSYLHEXAPEPTIDE, MODIFIED AMADORIASE
EA201590962A1 (ru) Новые соединения
BR112013003530A2 (pt) ''produto farmacêutico, kit, uso e preparações''
BR112014008089A2 (pt) método para diagnosticar o mal de alzheimer, uso do método, e, kit para a realização do método
BR112013008704A2 (pt) "dispensador com bobina coletora de resíduos, e métodos de uso"
BR112014026873A2 (pt) método cosmético, composição cosmética e uso.
EA201590823A1 (ru) 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора
CL2014003123A1 (es) 5-amino [1,4], tiazinas como inhibidores de bace1; uso del compuesto contra la enfermedad de alzheimer.
UY34785A (es) Formulación en cápsulas solubilizadas de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metoxiisoquinolin-1-iloxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletilo
CL2013000069A1 (es) Compuestos derivados de heterociclos fusionados, moduladores s1p; composicion farmaceutica; y uso en enfermedades neurodegenerativas.
BR112015003032A2 (pt) anticorpos anti-jagged e métodos de utilização'.